You are here

Article Text

Article menu
Download PDFPDF
Letter
Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy

https://doi.org/10.1136/annrheumdis-2016-210820

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Contributors OL, the corresponding author, states that all the authors listed have contributed to the work.

    • Funding LA: research funding: Novartis, Pfizer.

    • Competing interests Honoraria: SC for Bristol-Myers Squibb, Janssen, Merck Sharp & Dohme and Roche. LA for Novartis, Pfizer, BMS, Sanofi and Ipsen. OL for Merck Sharp Dohme and Genzyme.

    • Ethics approval Gustave Roussy ethical committee.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • ↵i Registre des Effets Indésirables Sévères des Anticorps Monoclonaux Immunomodulateurs en Cancérologie.